139 related articles for article (PubMed ID: 35092841)
21. Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: preliminary results of a risk-stratified phase I dose escalation study.
Adkison JB; Khuntia D; Bentzen SM; Cannon GM; Tome WA; Jaradat H; Walker W; Traynor AM; Weigel T; Mehta MP
Technol Cancer Res Treat; 2008 Dec; 7(6):441-7. PubMed ID: 19044323
[TBL] [Abstract][Full Text] [Related]
22. Five- Versus Ten-Fraction Regimens of Stereotactic Body Radiation Therapy for Primary and Metastatic NSCLC.
Steber CR; Hughes RT; Soike MH; Jacobson T; Helis CA; Farris JC; Farris MK
Clin Lung Cancer; 2021 Jan; 22(1):e122-e131. PubMed ID: 33046359
[TBL] [Abstract][Full Text] [Related]
23. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
[TBL] [Abstract][Full Text] [Related]
24. Neo-adjuvant chemotherapy followed by either continuous hyper-fractionated accelerated radiation therapy week-end less or conventional chemo-radiotherapy in locally advanced NSCLC-A randomised prospective single institute study.
Kumar R; Kumar HS; Paramanandhan M; Purohit R; Sharma N; Jakhar SL; Sharma S; Maharia S; Rai RK
J Cancer Res Ther; 2020; 16(4):860-866. PubMed ID: 32930131
[TBL] [Abstract][Full Text] [Related]
25. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
26. How Should Palliative Thoracic Radiotherapy Be Fractionated for Octogenarians with Lung Cancer?
Nieder C; Yobuta R; Mannsåker B; Dalhaug A
In Vivo; 2018; 32(2):331-336. PubMed ID: 29475917
[TBL] [Abstract][Full Text] [Related]
27. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
Ladbury CJ; Rusthoven CG; Camidge DR; Kavanagh BD; Nath SK
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):346-355. PubMed ID: 31175902
[TBL] [Abstract][Full Text] [Related]
28. Comparison of survival outcomes among standard radiotherapy regimens in limited-stage small cell lung cancer patients receiving concurrent chemoradiation.
Rutter CE; Park HS; Corso CD; Yeboa DN; Mancini BR; Lester-Coll NH; Kim AW; Decker RH
Lung Cancer; 2015 Nov; 90(2):243-8. PubMed ID: 26277031
[TBL] [Abstract][Full Text] [Related]
29. A retrospective analysis of survival outcomes for two different radiotherapy fractionation schedules given in the same overall time for limited stage small cell lung cancer.
Bettington CS; Tripcony L; Bryant G; Hickey B; Pratt G; Fay M
J Med Imaging Radiat Oncol; 2013 Feb; 57(1):105-12. PubMed ID: 23374562
[TBL] [Abstract][Full Text] [Related]
30. Radiation therapy of stage I and II non-small cell lung cancer (NSCLC).
Zierhut D; Bettscheider C; Schubert K; van Kampen M; Wannenmacher M
Lung Cancer; 2001 Dec; 34 Suppl 3():S39-43. PubMed ID: 11740992
[TBL] [Abstract][Full Text] [Related]
31. Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer.
Amini A; Lin SH; Wei C; Allen P; Cox JD; Komaki R
Radiat Oncol; 2012 Mar; 7():33. PubMed ID: 22420631
[TBL] [Abstract][Full Text] [Related]
32. Three- Versus Five-Fraction Regimens of Stereotactic Body Radiotherapy for Peripheral Early-Stage Non-Small-Cell Lung Cancer: A Two-Institution Propensity Score-Matched Analysis.
Ma SJ; Cummings M; Serra LM; Syed YA; Hermann GM; Chen Y; Milano MT; Singh AK; Gomez-Suescun JA; Singh DP
Clin Lung Cancer; 2018 May; 19(3):e297-e302. PubMed ID: 29254649
[TBL] [Abstract][Full Text] [Related]
33. A treatment planning study evaluating a 'simultaneous integrated boost' technique for accelerated radiotherapy of stage III non-small cell lung cancer.
Dirkx ML; van Sörnsen De Koste JR; Senan S
Lung Cancer; 2004 Jul; 45(1):57-65. PubMed ID: 15196735
[TBL] [Abstract][Full Text] [Related]
34. Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC.
Schild SE; Pang HH; Fan W; Stinchcombe TE; Vokes EE; Ramalingam SS; Bradley JD; Kelly K; Wang X
J Thorac Oncol; 2018 Aug; 13(8):1171-1182. PubMed ID: 29689435
[TBL] [Abstract][Full Text] [Related]
35. Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer.
Matsuura K; Kimura T; Kashiwado K; Fujita K; Akagi Y; Yuki S; Murakami Y; Wadasaki K; Monzen Y; Ito A; Kagemoto M; Mori M; Ito K; Nagata Y
Int J Clin Oncol; 2009 Oct; 14(5):408-15. PubMed ID: 19856048
[TBL] [Abstract][Full Text] [Related]
36. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.
; Bentzen SM; Agrawal RK; Aird EG; Barrett JM; Barrett-Lee PJ; Bliss JM; Brown J; Dewar JA; Dobbs HJ; Haviland JS; Hoskin PJ; Hopwood P; Lawton PA; Magee BJ; Mills J; Morgan DA; Owen JR; Simmons S; Sumo G; Sydenham MA; Venables K; Yarnold JR
Lancet Oncol; 2008 Apr; 9(4):331-41. PubMed ID: 18356109
[TBL] [Abstract][Full Text] [Related]
37. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation.
Videtic GM; Truong PT; Dar AR; Yu EW; Stitt LW
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):709-16. PubMed ID: 14529775
[TBL] [Abstract][Full Text] [Related]
38. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
[TBL] [Abstract][Full Text] [Related]
39. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.
Curran WJ; Paulus R; Langer CJ; Komaki R; Lee JS; Hauser S; Movsas B; Wasserman T; Rosenthal SA; Gore E; Machtay M; Sause W; Cox JD
J Natl Cancer Inst; 2011 Oct; 103(19):1452-60. PubMed ID: 21903745
[TBL] [Abstract][Full Text] [Related]
40. Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?
Ma JT; Sun L; Sun X; Xiong ZC; Liu Y; Zhang SL; Huang LT; Han CB
Radiat Oncol; 2017 Feb; 12(1):34. PubMed ID: 28143532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
